key: cord-0960025-et5ekue7
authors: Suthar, Mehul S.; Zimmerman, Matthew G.; Kauffman, Robert C.; Mantus, Grace; Linderman, Susanne L.; Hudson, William H.; Vanderheiden, Abigail; Nyhoff, Lindsay; Davis, Carl W.; Adekunle, Seyi; Affer, Maurizio; Sherman, Melanie; Reynolds, Stacian; Verkerke, Hans P.; Alter, David N.; Guarner, Jeannette; Bryksin, Janetta; Horwath, Michael; Arthur, Connie M.; Saakadze, Natia; Smith, Geoffrey Hughes; Edupuganti, Srilatha; Scherer, Erin M.; Hellmeister, Kieffer; Cheng, Andrew; Morales, Juliet A.; Neish, Andrew S.; Stowell, Sean R.; Frank, Filipp; Ortlund, Eric; Anderson, Evan; Menachery, Vineet D.; Rouphael, Nadine; Mehta, Aneesh; Stephens, David S.; Ahmed, Rafi; Roback, John D.; Wrammert, Jens
title: Rapid generation of neutralizing antibody responses in COVID-19 patients
date: 2020-06-08
journal: Cell Rep Med
DOI: 10.1016/j.xcrm.2020.100040
sha: b707d10231042f9b541042bbc3b83635b7eab8e9
doc_id: 960025
cord_uid: et5ekue7

Summary SARS-CoV-2, the virus responsible for COVID-19, is causing a devastating global pandemic and there is a pressing need to understand the development, specificity, and neutralizing potency of humoral immune responses during acute infection. We report a cross-sectional study of antibody responses to the receptor-binding domain (RBD) of the spike protein and virus neutralization activity in a cohort of 44 hospitalized COVID-19 patients. RBD-specific IgG responses are detectable in all patients 6 days after PCR confirmation. Isotype switching to IgG occurs rapidly, primarily to IgG1 and IgG3. Using a clinical SARS-CoV-2 isolate, neutralizing antibody titers are detectable in all patients by 6 days after PCR confirmation and correlate with RBD-specific binding IgG titers. The RBD-specific binding data were further validated in a clinical setting with 231 PCR-confirmed COVID-19 patient samples. These findings have implications for understanding protective immunity against SARS-CoV-2, therapeutic use of immune plasma, and development of much-needed vaccines.

COVID-19 is a global pandemic. There is a pressing need to understand the immunological 46 response that mediates protective immunity to SARS-CoV-2. Antibody responses to the spike 47 (S) protein are thought to be to the primary target of neutralizing activity during viral infection, 48

conferring superior protective immunity compared to the membrane (M), envelope (E), and 49 nucleocapsid proteins [1] [2] [3] . The S glycoprotein is a class I viral fusion protein that exists as a 50 metastable prefusion homotrimer consisting of individual polypeptide chains (between 1100-51 1600 residues in length) responsible for cell attachment and viral fusion 4-6 . Each of the S protein 52 protomers is divided into two distinct regions, the S 1 and S 2 subunits 4, 7 . The S 1 subunit is a V-53 shaped polypeptide with four distinct domains, Domains A, B, C, and D, with Domain B 54 functioning as the receptor-binding domain (RBD) for most coronaviruses, including the 55 pathogenic β-coronaviruses such as SARS-CoV-2, SARS and MERS ( Fig. 1A; Fig. S1A ) 7-10 . 56 Recent studies have shown that the SARS-CoV-2 RBD interacts with the ACE2 receptor for 57 cellular attachment 5, 6, 10 . Sequence analysis of the RBD shows extensive homology in this region 58 to SARS (73%). In contrast, MERS and other seasonal coronaviruses show minimal sequence 59 homology to the SARS-CoV-2 RBD (7-18%) (Fig. 1B) . Herein, we set out to understand the 60 development, specificity, and neutralizing potency of the humoral immune response against the 61 RBD of the SARS-CoV-2 spike protein during acute infection. 62

To determine the magnitude of antibody responses, Ig isotype, and IgG subclass usage against 65 the RBD of the SARS-CoV-2 spike protein, we analyzed a cohort of acutely infected COVID-19 66 patients (n=44) enrolled at two hospitals in the Emory Healthcare System in Atlanta (Emory 67 University Hospital and Emory University Hospital Midtown). These patients were recruited 68 from both the inpatient ward and the ICU (patient details are provided in Table 1 ). These 69 samples represent a cross-section of days after patient-reported symptom onset (3-30 days) and 70 PCR confirmation (2-19 days). As healthy controls, we used plasma samples collected at 71 baseline in a vaccine study performed in early 2019 (n=32). The RBD protein was cloned and 72 expressed in mammalian cells (Fig. S1B) and was validated by ELISA using CR3022, a SARS-73 specific human monoclonal antibody that cross-reacts with SARS-CoV-2 11 (Fig. S1C) . Size 74 exclusion chromatography shows that the recombinant RBD protein is homogenous and does not 75 form aggregates (Fig. S1D) . We found that a majority of COVID-19 patients (36 out of 44) 76 developed RBD-specific class-switched IgG responses ( Fig. 1C ) (mean titer:18500, range: <100-77 142765). These patients also showed IgM and IgA responses of lower magnitude as compared to 78 IgG (IgM mean titer: 3731, range:<100-40197 and IgA mean titer: 973, range: <100-19918). All 79 of the negative controls were below the limit of detection in the endpoint analysis for binding to 80 the RBD antigen (Fig. 1C, red) . A representative RBD-specific IgG ELISA assay for a subset of 81 these donors is shown in Figure 1D to illustrate the dynamic range of these measurements. A 82 number of the COVID-19 patient samples that scored either negative or low in the RBD IgG 83 ELISA had higher titers of IgM (Fig. 1E, green) . Finally, IgG subclass analysis showed that the 84 COVID-19 patients exclusively made RBD-specific IgG1 and IgG3, with no detectable IgG2 or 85 IgG4 (Fig. 1F) . Taken together, these findings illustrate that antibody class-switching to IgG 86 occurs early during acute infection. 87

We next determined the neutralization capacity of samples from the cohort of acutely infected 90 COVID-19 patients. We have developed a focus reduction neutralization titer (FRNT) assay for 91 SARS-CoV-2. In this assay, COVID-19 patient plasma is incubated with a clinical isolate of 92 SARS-CoV-2 followed by infection of VeroE6 cells 12 . The neutralization potency of the plasma 93 sample is measured by the reduction in virally-infected foci. We screened plasma from COVID-94 19 patients (n=44) and found that a majority of the samples (40/44) showed neutralization 95 capacity, with titers ranging from 1:5763 to 1:55 ( Fig. 2A) . A representative example of viral 96 neutralization is shown in Figure 2b where pre-incubation with control plasma yields about 250 97 foci whereas the COVID-19 patient sample completely inhibited the formation of infected foci 98 ( Fig. 2B ). Representative neutralization curves for a subset of samples are shown to illustrate the 99 dynamic range of the results obtained (Fig. 2C) . A plaque reduction neutralization titer (PRNT) 100 assay is the classic method for determining the neutralization capacity of a plasma sample 101 against coronavirus infection 13 . To confirm the efficiency of these two assays, we compared the 102 neutralization titers between a standard PRNT assay and an FRNT assay for a subset of the 103 patient samples (n=9). Overall, we observed a strong positive correlation between these two 104 assays (Fig. 2D) , demonstrating the robustness of the FRNT assay. Overall, these findings 105 demonstrate that neutralizing antibody responses are generated early during acute COVID-19 106 infection. 107 108

The patient samples were collected across a range of days after symptom onset or PCR 110 confirmation of SARS-CoV-2 infection (Table 1) . To understand the relationship between these 111 variables and RBD-specific IgG antibody titers and viral neutralization potency, we performed 112 correlation analyses. In all cases, we observed significant correlations between the number of 113 days elapsed after symptom onset or positive PCR test and the RBD-specific IgG titer or viral 114 neutralization titer (Fig. 3) . Several key points regarding the kinetics of antibody responses can 115 be made from this correlation analysis. Antibody responses against the RBD (Fig. 3A) , as well as 116 SARS-CoV-2 virus neutralization titers (Fig. 3B ), can be detected in a majority of patients 117 around day 8 after symptom onset. When the number of days after PCR confirmation is used to 118 assess the duration of infection, both RBD-binding titers (Fig. 3C ) and viral neutralization titers 119 ( Fig. 3D ) can be detected in many patients already between days 2-6. Beyond 6 days post-PCR 120 confirmation, patients display both antibody binding and neutralization titers. Taken together, 121 these findings illustrate that both RBD-specific and neutralizing antibody responses occur 122 rapidly after SARS-CoV-2 infection. 123

We observed a wide range of RBD-specific and neutralizing antibody responses across the 127 cohort of acutely infected COVID-19 patients. We found that the magnitude of RBD-specific 128

IgG titers positively correlated with neutralization titers (r 2 = 0.7; p<0.0001; Fig. 4A ). Overall, 129

we observed viral neutralization activity in 40 out of 44 samples from acutely infected COVID-130 19 patients. 131 132 We next validated the RBD-specific IgG ELISA for high-throughput testing at the Emory 133

Medical Laboratories. For these analyses, we collected serum from 231 PCR-confirmed COVID-134 19 patient samples within the first 22 days after PCR confirmation (Table S1 ). In addition, 490 135 samples collected in 2019 were used as negative controls. The patient samples were grouped 136 from 0-3 days, 4-6 days, and 7 or more days after PCR confirmation and analyzed using a high-137 throughput clinical RBD ELISA. The cumulative results of these efforts are shown as receiver 138 operating characteristic (ROC) curves (Fig. 4B ). This assay is almost perfectly discriminatory by 139 day 7 after PCR confirmation, with an area under the curve (AUC) of 1.00 (n=83). When utilized 140 earlier in the disease course, the performance of this diagnostic assay is reduced. When the RBD 141 specific IgG ELISA were analyzed for the samples collected closer to the time of infection, the 142 AUC for the day 4-6 group (n=76) and the day 0-3 group (n=72) fell to 0.96 and 0.89, 143 respectively. Using an OD cut-off of 0.175 resulted in calculated sensitivity and specificity 144 values of 97.5% and 98%, respectively. Taken together, these findings demonstrate that RBD-145 specific IgG titers could be used as a surrogate of neutralization activity against SARS-CoV-2 146 infection and that the RBD assay is highly specific and sensitive. The appearance of high titer neutralizing antibody responses early after the infection is 173 promising and may offer some degree of protection from re-infection. Future studies will need to 174 define the neutralizing titer which constitutes a robust correlate of protective immunity and 175 determine the durability of these responses over time 18 . This information will be essential for 176 ongoing vaccine development efforts 19 Laboratories. We also acknowledge thorough and rapid chart reviews by Kari Broder. We thank 197

Guido Silvestri for helpful discussions. We thank Michael Konomos for help with generating the 198 graphical abstract. Finally, we thank all the participating patients, and the hospital staff caring for 199 them. Office 365 v16, and a custom software package was used to iteratively compute the false positive 433 rate (1 -specificity) and true positive rate (sensitivity) at every OD cutoff level for each cohort. 434

The false-positive rates (x) and true positive rates (y) were then rendered as scatter plots to 435 generate the ROC curves. Correlations analyses were done by log transforming RBD binding 436 titers or neutralization titers, followed by linear regression analysis. The R 2 and p-value are 437 reported in each figure. 438 439

Full-length spike protein A. B. C. 

SARS-CoV and emergent coronaviruses: 441 viral determinants of interspecies transmission

Vaccine efficacy in senescent mice challenged with 444 recombinant SARS-CoV bearing epidemic and zoonotic spike variants

Contributions of the structural proteins of severe acute respiratory 447 syndrome coronavirus to protective immunity

The coronavirus spike 449 protein is a class I virus fusion protein: structural and functional characterization of the fusion 450 core complex

SARS-CoV-2 Cell Entry 453 Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human 457 ACE2

Structural insights into coronavirus entry

Structure of SARS coronavirus spike 461 receptor-binding domain complexed with receptor

Molecular basis of binding between novel human coronavirus MERS-CoV and its 464 receptor CD26

Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Human monoclonal 470 antibody combination against SARS coronavirus: synergy and coverage of escape mutants

Severe Acute Respiratory Syndrome Coronavirus 2 from 474 Patient with Coronavirus Disease, United States

Structural basis for potent cross-neutralizing human monoclonal antibody protection 477 against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge

Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 481 patients

Severe Acute

Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 485 Patients. Emerg Infect Dis 26

Deployment of convalescent 488 plasma for the prevention and treatment of COVID-19

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Two-year prospective study of the humoral immune response of patients with 495 severe acute respiratory syndrome

SARS-CoV-2 Vaccines: Status Report

Rapid generation of fully human monoclonal antibodies specific to a vaccinating 500 antigen

Cryo-EM structure of the 2019-nCoV spike in the prefusion 503 conformation

• Cross-sectional study of 44 hospitalized COVID-19 patients.• RBD-specific IgG responses detectable in all patients 6 days after PCR confirmation.• Neutralizing titers are detectable in all patients 6 days after PCR confirmation.• RBD-specific IgG titers correlate with the neutralizing potency.

Suthar et al. report on a cross-sectional study of hospitalized COVID-19 patients suggesting a correlation between the SARS-CoV-2 receptor-binding-domain-specific IgG responses and virus neutralizing antibody responses. These findings have implications for understanding protective immunity against SARS-CoV-2, therapeutic use of immune plasma, and development of vaccines.